Allergan and Alcon settle dispute

Article

Allergan and Alcon have settled Allergan's patent infringement lawsuit, contending that Alcon's proposed brimonidine 0.15% product infringed two brimonidine-related patents owned by Allergan.

Allergan and Alcon have settled Allergan's patent infringement lawsuit, contending that Alcon's proposed brimonidine 0.15% product infringed two brimonidine-related patents owned by Allergan.

The suit, settled in the US District Court for the District of Delaware, USA, places three conditions on Alcon's marketing and distribution of its product. Alcon has agreed to a license beginning on September 30th 2009 in the US under both patents at issue; Alcon will not sell, offer for sale or distribute its brimonidine 0.15% until this date; thirdly, when its product does reach the market, it will pay Allergan royalties for sales in the US.

Allergan's range of brimonidine-containing products include the company's glaucoma medications Alphagan and Combigan.

Bird flies in to iCo

Canadian biotech company, iCo Therapeutics has announced that Dr. Alan Bird has joined its Strategic Advisory Team.

Bird is known for his pioneering research in the field of retinal disease, in particular for his part in identifying the genes that cause certain eye diseases. His career began at Moorfield's Eye Hospital, London, UK, where he made significant contributions in the development of treatments for retinal vascular disease and genetic and degenerative retinal disorders.

Bird has been the recipient of a number of prestigious awards including the Alcon Research Award, The Helen Keller Prize, The Kayser Award and the Jules Francois Medal. Earlier this year he was honoured with a lifetime achievement award by the Macular Society.

NicOx/Pfizer relationship blossoms

Pfizer is due to make an upfront payment of €8 million and NicOx will receive €3 million in research funding on each anniversary of the agreement for the duration of the research programme. Pfizer will also make a €15 million equity investment in NicOx, subject to approval by the shareholders. Furthermore, NicOx may receive total potential milestones in excess of €300 million in the ophthalmology field and royalties on each product marketed as a result of the collaboration.

NicOx has also announced promising preclinical results from its existing collaboration with Pfizer, which is focused on a single class of compounds in glaucoma.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
© 2025 MJH Life Sciences

All rights reserved.